Urovant Sciences Ltd. (UROV)
| Market Cap | 512.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -158.17M |
| Shares Out | 31.25M |
| EPS (ttm) | -5.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $16.16 |
| Previous Close | $16.15 |
| Change ($) | 0.01 |
| Change (%) | 0.06% |
| Day's Open | 16.15 |
| Day's Range | 16.15 - 16.17 |
| Day's Volume | 5,012 |
| 52-Week Range | 7.16 - 16.19 |
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies -UROV, INFO, WDR, CKH, EIGI
NEW YORK, Dec. 28, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Urovant Sciences Ltd. (NASDAQ: UROV) concern...
GEMTESA® is the second FDA approval for the Sumitovant Biopharma family of companies in the past weekGEMTESA® is the first new oral branded OAB medication approved by the U.S. FDA since 2012 a...
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (ND...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Urovant ...
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--UROV Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary ...
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study
New York, New York--(Newsfile Corp. - November 18, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://or...
BERWYN, Pa., Nov. 18, 2020 /PRNewswire/ -- RM LAW, P.C. announces an investigation on behalf of Urovant Sciences Ltd. ("Urovant" or the "Company") (NASDAQ: UROV) regarding possible breaches of...
The acquisition of Urovant Sciences by majority owner Sumitomo significantly undervalues the company's lead asset vibegron. The buyout price implies approximately $250 million in peak sales fo...
NEW YORK, Nov. 13, 2020 /PRNewswire/-- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New...
NEW YORK, Nov. 13, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Urovant Sciences Ltd. ("UROV"...
The company's biggest shareholder plans to acquire all of Urovant.
Urovant Sciences (UROV) has entered into an acquisition agreement with Sumitovant Biopharma that has UROV stock soaring on Friday. The post UROV Stock: 9 Things to Know About the Urovant Scien...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Urovant Sciences Ltd. (NASDAQ: UROV) to Sumitovant Biopharma Ltd. for $16.2...
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares
NEW YORK and LONDON and IRVINE, Calif. and BASEL, Switzerland, Nov. 12, 2020 /PRNewswire/ -- Sumitovant Biopharma and Urovant Sciences (Nasdaq: UROV) today announced that they have entered int...
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Present at the Jefferies Virtual London Healthcare Conference
Urovant Sciences' (UROV) CEO Jim Robinson on Q2 2020 Results - Earnings Call Transcript
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Reports Second Quarter Fiscal Year 2020 Results
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
Urovant's valuation is reasonable when compared to the potential sales peak of Vibegron.
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Present at the H.C.
Urovant Sciences Ltd. (UROV) CEO James Robinson on Q1 2020 Results - Earnings Call Transcript
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Reports Fiscal First Quarter 2020 Results
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results
Urovant Sciences Ltd (UROV) on Q4 2019 Results - Earnings Call Transcript
Urovant Sciences Ltd (UROV) CEO James Robinson on Q4 2019 Results - Earnings Call Transcript
Urovant Sciences: Still A Hidden Gem With Multiple Catalysts Approaching
Urovant Has Upside Potential Heading Into Vibegron's PDUFA Later This Year
The company has a diversified pipeline in that Vibegron is being explored for several indications that could bring in billions of dollars.
Urovant Sciences' (UROV) CEO Keith Katkin on Q3 2019 Results - Earnings Call Transcript
Urovant Sciences Is A Hidden Gem With A Blockbuster Drug Likely To Be Approved This Year And 'Short Squeeze' Potential. PT: $43
Urovant Sciences Ltd (NASDAQ: UROV) has submitted a New Drug Application (NDA) to the U.S.
Urovant Sciences Ltd. (UROV) CEO Keith Katkin on Q2 2019 Results - Earnings Call Transcript
Urovant Sciences Limited (UROV) CEO Keith Katkin on Q1 2019 Results - Earnings Call Transcript
Finisar falls, Urovant Sciences rises on financial results.
Urovant Sciences Limited (UROV) CEO Keith Katkin on Q4 2018 Results - Earnings Call Transcript
About UROV
Urovant Sciences, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant... [Read more...]
| Industry Biotechnology | IPO Date Sep 27, 2018 |
| CEO James A. Robinson Jr. | Employees 70 |
| Stock Exchange NASDAQ | Ticker Symbol UROV |
Analyst Forecasts
According to 3 analysts, the average rating for UROV stock is "Hold." The 12-month stock price forecast is 16.17, which is an increase of 0.06% from the latest price.